1187582-53-1 Usage
General Description
1-Methyl-4-piperidinemethanamine dihydrochloride is a chemical compound that is typically used in laboratory research for a variety of applications. The chemical structure consists of a methyl group (CH3) and a piperidine ring, in addition to a methanamine group and two hydrogen chloride ions. It is commonly synthesized via organic chemistry derivatization methods. The compound is generally solid in its stable state, and should be stored in a cool, dry, ventilated location. 1-Methyl-4-piperidinemethanamine dihydrochloride should be handled with care as it may pose certain hazards if improperly handled.
Check Digit Verification of cas no
The CAS Registry Mumber 1187582-53-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,8,7,5,8 and 2 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1187582-53:
(9*1)+(8*1)+(7*8)+(6*7)+(5*5)+(4*8)+(3*2)+(2*5)+(1*3)=191
191 % 10 = 1
So 1187582-53-1 is a valid CAS Registry Number.
InChI:InChI=1S/C7H16N2.2ClH/c1-9-4-2-7(6-8)3-5-9;;/h7H,2-6,8H2,1H3;2*1H
1187582-53-1Relevant articles and documents
Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2- ones as potent and selective mTOR kinase inhibitors
Mortensen, Deborah S.,Perrin-Ninkovic, Sophie M.,Harris, Roy,Lee, Branden G.S.,Shevlin, Graziella,Hickman, Matt,Khambatta, Gody,Bisonette, Rene R.,Fultz, Kimberly E.,Sankar, Sabita
supporting information; experimental part, p. 6793 - 6799 (2012/01/03)
We report here the discovery of a novel series of selective mTOR kinase inhibitors. A series of imidazo[4,5-b]pyrazin-2-ones, represented by screening hit 1, was developed into lead compounds with excellent mTOR potency and exquisite kinase selectivity. Potent compounds from this series show >1000-fold selectivity over the related PI3Kα lipid kinase. Further, compounds such as 2 achieve mTOR pathway inhibition, blocking both mTORC1 and mTORC2 signaling, in PC3 cancer cells as measured by inhibition of pS6 and pAkt (S473).
